GA-CYBLE
6.8.2024 11:03:28 CEST | Business Wire | Press release
Cyble, a global leader in AI-powered Gen 3 Cyber Threat Intelligence and digital risk protection, is excited to announce the appointment of Ernest Fung as its new Chief Financial Officer (CFO).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240802353537/en/
Cyble Appoints Ernest Fung as Chief Financial Officer (Photo: Business Wire)
With a rich background in corporate finance and investment strategies, Ernest brings invaluable expertise and leadership to Cyble. His role will be instrumental in enhancing the company’s financial strategy and driving its global expansion.
Ernest’s distinguished career spans over two decades across several sectors. He previously served as Chief Investment Officer at GoTo Group, Indonesia’s largest technology company. where he led GoTo’s $1 billion IPO, and secured over $1.3 billion in funding in GoTo’s pre-IPO financing. Ernest also served as Chief Investment Officer at Tokopedia, the leading e-commerce company in Indonesia, where he led the $18 billion merger with Gojek to form GoTo Group. Prior to his leadership positions at GoTo and Tokopedia, Ernest led International Corporate Development at JD.com, one of the largest e-commerce companies in China, and was a Director of Technology Investment Banking at Citigroup.
Beenu Arora, CEO of Cyble, stated, “We are delighted to welcome Ernest to our executive team. His understanding of financial strategy for managing high-growth companies will be invaluable as we scale our operations globally.”
Manish Chachada, COO of Cyble, added, “Ernest’s expertise in financial management and his strategic vision will be crucial as we expand our product offerings.”
"I am excited to join Cyble, one of the most innovative cybersecurity companies in the world," said Ernest. "I look forward to working closely with the Cyble team to achieve the company’s vision."
Cyble has recently received significant accolades, including being named an Innovation Leader in the Frost Radar™: Cyber Threat Intelligence 2024 by Frost & Sullivan. The company was also recognized in three Gartner Hype Cycle™ reports for the DRPS category, featured in Forrester's ASM Landscape 2024 report, and highlighted as a leader in G2’s Dark Web Monitoring Providers grid.
About Cyble
Cyble, the world's fastest-growing Gen 3 cyber threat intelligence company, offers comprehensive coverage across adversaries, infrastructure, exposures, weaknesses, and targets. Leveraging AI and ML, Cyble provides critical intelligence to help governments and enterprises protect citizens and infrastructure. Headquartered in Atlanta, Georgia, Cyble also has offices in Australia, Malaysia, Singapore, Dubai, Saudi Arabia, and India.
To learn more visit http://www.cyble.com/request-demo
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240802353537/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Carnegie Mellon University and Cleveland Clinic Develop AI System to Interpret Cardiac MRI Scans with Enhanced Accuracy21.5.2026 14:05:00 CEST | Press release
Trained on more than 13,000 patient studies, novel system significantly outperforms existing models by up to 35% A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521762286/en/ A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. The novel system, called CMR-CLIP, is d
Otovo Hits 30,000 Customers in Under a Year, Tackling the Growing ‘Solar Service Crisis’21.5.2026 14:00:00 CEST | Press release
A growing wave of unsupported solar systems and rising electricity prices are creating strong demand for Otovo’s energy service platform Otovo ASA (“Otovo”), a leading global energy service provider for residential and commercial customers, today announced it has reached 30,000 customers across the U.S. and Europe. A total of 20,000 customers have enrolled in Otovo Care, the Company’s membership-based home and commercial energy service, which is powered by Otovo’s industry-leading AI platform, Endurance™. “Reaching 30,000 customers in less than year is proof positive that home and business owners value their power systems,” said William J. (John) Berger, CEO of Otovo. “The ‘solar service crisis’ that is leaving millions of orphaned energy systems without support is driving strong interest in our Otovo Care membership program. Every day your home or commercial power system is not working, you are throwing money away. Otovo’s rapid response service platform keeps you up and running, ensu
The Live Moment Effect: Genius Sports and MediaScience Study Finds Specific Moments in Live Sports Can Double Unaided Brand Recall21.5.2026 14:00:00 CEST | Press release
New research shows that brands aligned with emotionally heightened moments in live sports can improve ad effectiveness Genius Sports Limited (NYSE: GENI), a global leader in real-time sports data, today released new biometric research conducted with MediaScience showing that ads delivered immediately after emotionally heightened moments in live sports can double unaided brand recall. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521475265/en/ The Live Moment Effect report from Genius Sports and MediaScience. The study, The Live Moment Effect, finds that advertising effectiveness is significantly influenced by a viewer’s emotional state immediately before an ad is shown. In controlled biometric testing, ads shown after high-intensity sporting moments, such as near-scoring plays or crucial momentum shifts, delivered approximately double the unaided brand recall of baseline conditions. The Moment Before the Ad Matters The r
Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer21.5.2026 14:00:00 CEST | Press release
Precemtabart tocentecan (Precem-TcT) is investigated as a potential first-in-class anti-CEACAM5 ADC, for the treatment of metastatic CRC (mCRC) CEACAM5 is overexpressed in the majority of colorectal tumors (~90%), and requires no patient selection Significant unmet need remains for clinically meaningful innovation in colorectal cancer (CRC), the second leading cause of cancer death worldwide Not intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced that the first patient has been dosed in the Phase 3 PROCEADE®-CRC-03 trial (NCT07549412). The study is evaluating precemtabart tocentecan (Precem‑TcT), a potential first‑in‑class investigational anti‑CEACAM5 antibody‑drug conjugate (ADC), for the treatment of metastatic colorectal cancer (mCRC). “Leveraging our novel payload‑linker technology, Precem‑TcT is the first CEACAM5‑targeted ADC in clinical studies with an exatecan payload, rationally designed for stability and enhanced cancer
Baszucki Group Funds Oxford University Clinical Trial of Ketogenic Therapy for Early Psychosis21.5.2026 13:00:00 CEST | Press release
Randomized controlled trial will evaluate both symptom progression and underlying biology Baszucki Group today announced a £1.17 million grant to support a randomized controlled trial at the University of Oxford assessing the feasibility, safety, and efficacy of a ketogenic diet for patients at clinical high risk of psychosis (CHR-P). Researchers will test this nutritional therapy's ability to improve patients' mental and physical health. This project builds on a growing body of research suggesting the potential of metabolic therapies in treating serious mental illness. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521877110/en/ Baszucki Group Funds £1.17 Million for University of Oxford Trial of Ketogenic Therapy for Early Psychosis Psychotic disorders carry a massive personal burden and are associated with a lower life expectancy. Psychosis does not develop immediately, but typically emerges following a period of early
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom